Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Report 2026

Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Overview

• Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler market size has reached to $0.81 billion in 2025 • Expected to grow to $2.28 billion in 2030 at a compound annual growth rate (CAGR) of 23% • Growth Driver: Rising Cancer Prevalence Fueling The Growth Of The Market Due To The Need For Optimized, Personalized, And Timely Radiation Treatment Planning • Market Trend: Developing AI-Driven Tele-Oncology Dose Prediction Platforms To Enhance Treatment Planning Efficiency And Enable Personalized Radiation Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market?

An artificial intelligence (AI) tele-oncology radiation dose scheduler is a digital system that uses artificial intelligence to assist clinicians in planning, adjusting, and optimizing radiation dose schedules remotely. It analyzes clinical, imaging, and treatment parameters to recommend precise dosing decisions tailored to each patient. It enhances accuracy, reduces planning time, and supports remote oncology workflows. The main components of AI tele-oncology radiation dose schedulers are software, hardware, and services. Software comprises artificial intelligence–enabled scheduling and planning platforms that automate dose planning, workflow coordination, and resource optimization for remote and centralized radiation oncology operations. These solutions are built on technologies such as machine learning algorithms, natural language processing, computer vision, and predictive analytics, deployed through on-premise, cloud-based, and hybrid models, used in applications including auto-contouring and segmentation, treatment plan generation and optimization, dose prediction and quality assurance, workflow and resource scheduling optimization, and adaptive radiotherapy planning, among end users such as hospitals, cancer treatment centers, research institutes, and others.

What Is The Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Growth Forecast?

The artificial intelligence (AI) tele-oncology radiation dose scheduler market size is expected to see exponential growth in the next few years. It will grow to $2.28 billion in 2030 at a compound annual growth rate (CAGR) of 23.0%. The growth in the forecast period can be attributed to expansion of tele-oncology networks, adoption of ai-enabled treatment planning platforms, rising demand for automated dose calculation systems, uptake of cloud-based oncology scheduling modules, deployment of predictive oncology algorithms, development of remote radiotherapy review tools, demand for precision-based cancer care, integration of ai tools into oncology departments, partnerships between ai vendors and cancer centers, growing acceptance of tele-radiation workflows. Major trends in the forecast period include advancement in ai-driven radiotherapy dose prediction, advancement in cloud-based oncology scheduling platforms, advancement in real-time dose optimization engines, innovation in automated treatment planning systems, innovation in predictive oncology algorithms, innovation in virtual radiation oncology workflows, integration of tele-oncology with hospital info systems, integration of ai dose schedulers with imaging platforms, integration of remote dose-review tools for oncologists, integration of multi-center tele-radiation networks.

Global Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Segmentation

1) By Component: Software, Hardware, Services 2) By Technology: Machine Learning Algorithms, Natural Language Processing, Computer Vision, Predictive Analytics 3) By Deployment Mode: On-Premise (Local Installation), Cloud-Based (SaaS), Hybrid Deployment 4) By Application: Auto-Contouring And Segmentation (OAR Or Target), Treatment Plan Generation And Optimization, Dose Prediction And Quality Assurance (QA), Workflow And Resource Scheduling Optimization, Adaptive Radiotherapy Planning 5) By End-User: Hospitals, Cancer Treatment Centers, Research Institutes, Other End-Users Subsegments: 1) By Software: Analytics And Reporting Software, Recommendation Engine Software, Natural Language Processing Software, Machine Learning Model Management Tools, Computer Vision Software, Integration And API Management Software, Mobile And Web Application Software 2) By Hardware: AI-Optimized Servers, Edge Computing Devices, Sensors And IoT Devices, Smart Cameras, GPUs And AI Accelerators, Storage Systems, Networking And Connectivity Hardware 3) By Services: Consulting Services, Implementation And Integration Services, Training And Support Services, Managed AI Services, Maintenance And Upgradation Services, Custom AI Development Services, Data Management And Annotation Services

What Is The Driver Of The Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market?

The rising prevalence of cancer is expected to propel the growth of the artificial intelligence (AI) tele-oncology radiation dose scheduler market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells that can damage surrounding tissues and organs if not treated effectively. The prevalence of cancer is increasing due to lifestyle-related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Artificial intelligence (AI) tele-oncology radiation dose schedulers support cancer management by optimizing and personalizing radiation treatment plans through remote, data-driven analysis. They improve patient outcomes by ensuring accurate dosing, reducing treatment delays, and enabling consistent care across locations. For instance, in October 2025, according to NHS Digital, a UK government organisation, there were 354,820 new cancer diagnoses recorded in England in 2023, averaging 972 diagnoses per day and representing an increase of 8,605 cases compared to 2022, with prostate cancer being the most commonly diagnosed cancer at 58,137 new cases, reflecting a 6% increase in registrations compared to the previous year. Therefore, the rising prevalence of cancer is driving the growth of the artificial intelligence (AI) tele-oncology radiation dose scheduler industry.

Key Players In The Global Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market

Major companies operating in the artificial intelligence (AI) tele-oncology radiation dose scheduler market are IBM Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Varian Medical Systems Inc., Elekta AB, Shanghai United Imaging Healthcare Co. Ltd., Accuray Incorporated, Brainlab AG, RaySearch Laboratories AB, MIM Software Inc., Sun Nuclear Corp., DeepHealth, Radformation Inc., MVision AI Ltd., Mirada Medical Ltd., ViewRay Inc., Oncora Medical, Enlitic, Optellum Ltd.

Global Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Trends and Insights

Major companies operating in the AI tele‑oncology and radiation therapy market are focusing on developing advanced solutions, such as AI-powered dose prediction, to predict personalized radiation dose distributions in order to improve treatment planning efficiency. AI-powered dose prediction platforms are software solutions used to analyze imaging and anatomical data, generate clinically achievable 3D dose distributions, and support timely adjustments to optimize therapy. For instance, in March 2025, MVision AI, a Finland-based health‑tech company, launched Dose+. This AI-powered dose prediction platform incorporates specialized models for prostate and pelvic lymph node cases, tailors dose distributions to each patient’s anatomy, and supports integration with standard treatment planning systems via DICOM to facilitate efficient planning workflows. This launch represents a significant technological advancement by integrating AI-driven dose prediction into routine clinical practice, bridging traditional planning with automated, patient-specific optimization, and providing clinicians with a scalable, efficient solution for precise, personalized radiation therapy.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market?

In October 2024, Baylor College of Medicine, a US‑based academic health science centre, partnered with mVIZION.ai Inc. to advance AI innovations in radiation therapy planning and delivery. Through this collaboration, Baylor College of Medicine and mVIZION.ai aim to develop and refine AI‑powered radiation dose scheduling and optimisation tools that support personalised treatment regimens, reduce variability in therapy delivery, and improve clinical outcomes in oncology care. mVIZION.ai Inc. is a US‑based artificial intelligence healthcare company.

Regional Insights

North America was the largest region in the AI tele-oncology radiation dose scheduler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market?

The artificial intelligence (AI) tele-oncology radiation dose scheduler market consists of revenues earned by entities by providing services such as remote radiation dose planning services, AI-driven treatment scheduling, tele-consultation support for oncology dosing, cloud-based radiation planning assistance and real-time dose adjustment analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) tele-oncology radiation dose scheduler market consists of sales of AI radiation planning software, tele-oncology workflow platforms, cloud-based dose scheduling tools, automated treatment optimization algorithms, and radiation dose calculation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Report 2026?

The artificial intelligence (ai) tele-oncology radiation dose scheduler market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai) tele-oncology radiation dose scheduler industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.